The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer
Open accessAbstract
Lung cancer (LC) is the most prevalent cancer worldwide, and responsible for over 1.3 million deaths each year. Currently, LC has a low five year survival rates relative to other cancers, and thus, novel methods to screen for and diagnose malignancies are necessary to improve patient outcomes. Here, we report on a pilot-sized study to evaluate the potential of the sputum microbiome as a source of non-invasive bacterial biomarkers for lung cancer status and stage. Spontaneous sputum samples were collected from ten patients referred with possible LC, of which four were eventually diagnosed with LC (LC+), and six had no LC after one year (LC-). Of the seven bacterial species found in all samples, Streptococcus viridans was significantly higher in LC+ samples. Seven further bacterial species were found only in LC-, and 16 were found only in samples from LC+. Additional taxonomic differences were identified in regards to significant fold changes between LC+ and LC-cases, with five species having significantly higher abundances in LC+, with Granulicatella adiacens showing the highest level of abundance change. Functional differences, evident through significant fold changes, included polyamine metabolism and iron siderophore receptors. G. adiacens abundance was correlated with six other bacterial species, namely Enterococcus sp. 130, Streptococcus intermedius, Escherichia coli, S. viridans, Acinetobacter junii, and Streptococcus sp. 6, in LC+ samples only, which could also be related to LC stage. Spontaneous sputum appears to be a viable source of bacterial biomarkers which may have utility as biomarkers for LC status and stage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Reagent and laboratory contamination can critically impact sequence-based microbiome analyses
Salter, S. J., Cox, M. J., Turek, E. M., Calus, S. T., Cookson, W. O., Moffatt, M. F., Turner, P., Parkhill, J., Loman, N. J., & Walker, A. W. (2014) · BMC Biology · doi:10.1186/s12915-014-0087-z · Cited by 3,463 · cited 2×
“All DNA extractions were completed using the same FastDNA SPIN kit box to minimise the potential effect of extraction kit contamination, as previously reported [31].”
BackgroundMethodGlobal patterns of cancer incidence and mortality rates and trends
Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778
Analysis of the lung microbiome in the “healthy” smoker and in COPD.
Erb-Downward, J. R., Thompson, D. L., Han, M. K., Freeman, C. M., McCloskey, L., Schmidt, L. A., Young, V. B., Toews, G. B., Curtis, J. L., Sundaram, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016384 · Cited by 973 · cited 5×
“A history of previous lung disease such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, tuberculosis and pneumonia has been associated with an increased risk of developing lung cancer [6].”
BackgroundInfluentialVoynow, J. A., & Rubin, B. K. (2009) · Chest · doi:10.1378/chest.08-0412 · Cited by 504
Willner, D., Furlan, M., Haynes, M., Schmieder, R., Angly, F. E., Silva, J., Tammadoni, S., Nosrat, B., Conrad, D., & Rohwer, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007370 · Cited by 441 · cited 1×
“Other respiratory conditions have been studied with this method, such as cystic fibrosis, though with relatively small sample numbers, such as two [27], five [28], and ten [29].”
BackgroundThe lung microbiome in moderate and severe chronic obstructive pulmonary disease
Pragman, A. A., Kim, H. B., Reilly, C. S., Wendt, C., & Isaacson, R. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047305 · Cited by 437 · cited 4×
“A history of previous lung disease such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, tuberculosis and pneumonia has been associated with an increased risk of developing lung cancer [6].”
BackgroundInfluentialSpatial distribution of microbial communities in the cystic fibrosis lung
Willner, D., Haynes, M. R., Furlan, M., Schmieder, R., Lim, Y. W., Rainey, P. B., Rohwer, F., & Conrad, D. (2012) · The ISME Journal · doi:10.1038/ismej.2011.104 · Cited by 177
Cited by
Unexpected guests in the tumor microenvironment: microbiome in cancer
Wong-Rolle, A., Wei, H. K., Zhao, C., & Jin, C. (2021) · Protein & Cell · doi:10.1007/s13238-020-00813-8 · Cited by 313
Interplay between the lung microbiome and lung cancer
Mao, Q., Jiang, F., Yin, R., Wang, J., Xia, W., Dong, G., Ma, W., Yang, Y., Xu, L., & Hu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.036 · Cited by 254
Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.014 · Cited by 133
Tomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2081010 · Cited by 100
The Human Microbiome in Relation to Cancer Risk: A Systematic Review of Epidemiologic Studies
Huybrechts, I., Zouiouich, S., Loobuyck, A., Vandenbulcke, Z., Vogtmann, E., Pisanu, S., Iguacel, I., Scalbert, A., Indave, I., Smelov, V., et al. (2020) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0288 · Cited by 80
Metadata
- Authors
- Cameron, S. J. S., Lewis, K. E., Huws, S. A., Hegarty, M. J., Lewis, P. D., Pachebat, J. A., & Mur, L. A. J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-05-25
- Volume
- 12
- Issue
- 5
- Pages
- e0177062
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2617661002
- Cited by
- 182
- References
- 8
- FWCI
- 16.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.